Eisai (ESAIY) and Biogen (BIIB) announced that humanized anti- soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” has been approved for once every four weeks intravenous maintenance dosing by the Medicines and Healthcare products Regulatory Agency in the United Kingdom.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls
- Biogen upgraded to Buy from Hold at Stifel
- Biogen’s Hold Rating: Balancing Promising Growth with Revenue Challenges and Infrastructure Development
- Biogen to highlight progress in rare kidney disease at ASN Kidney Week
- Biogen price target raised to $157 from $155 at Bernstein